Trial Profile
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Patritumab (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms HER3-Lung
- Sponsors Daiichi Sankyo Company
- 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 06 Oct 2016 This trial is completed in Hungary (End date: 18 May 2016), according to European Clinical Trials Database.
- 31 May 2016 Status changed from recruiting to discontinued, according to a Daiichi Sankyo media release.